CLINICAL AND METABOLIC EFFECTS OF TAURINE IN REPRODUCTIVE AGE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To reveal taurine's effects on metabolism, menstrual and reproductive function in women with PCOS. Methods. A total of 44 women with PCOS were included in the study with ages ranging from 18 to 44. Patients were randomized into two groups: 1) «Dibicor» group, n=30; 2) «Placebo» group, n=14. Thirty patients received dibicor 500 mg twice a day, fourteen patients received placebo 500 mg twice a day. Duration of the therapy was 3 months. Anthropometric measurements, content of adipose tissue, blood pressure, pulse rate, lipid levels, 3-hours oral glucose tolerance test (OGTT, 75 gr glucose), ultrasound uterine and ovarian investigations were done both before and after the therapy. Results. In the study group systolic and diastolic blood pressures were decreased. Heart rate was decreased, while serum HDL cholesterol was significantly increased (p=0,03). Changes in glucose metabolism characterized with metabolic clearance improvement in peripheral tissue («MRCSTUM», p=0,017) due to increasing of insulin sensitivity and beta cell function («1-st Phase», p=0,072; «2-nd Phase», p=0,049). Modulation of metabolism with taurine was accompanied by ovarian function enhancement, normalization of menstrual cycle (p=0,079), formation of dominate follicle in 20% of women with previous history of anovulation. Conclusion. Administration of dibicor in women with PCOS modulates metabolic dysfunction and improves reproductive prognosis, and also has protective effects against diabetes and cardiovascular diseases.

Full Text

Restricted Access

About the authors

T. A ZYKOVA

Northern State Medical University; E.E. Volosevich First City Clinical Hospital

Email: tatyana@atnet.ru. 632739@mail.ru
Arkhangelsk, Russia

L. V ULEDEVA

Northern State Medical University; E.E. Volosevich First City Clinical Hospital

Email: lidya-uledeva@yandex.ru
Arkhangelsk, Russia

A. V STRELKOVA

Northern State Medical University; E.E. Volosevich First City Clinical Hospital

Email: alexstr@atknet.ru
Arkhangelsk, Russia

L. B KOPTYAEVA

E.E. Volosevich First City Clinical Hospital

Email: larabron@mail.ru
Arkhangelsk, Russia

References

  1. Bart C.J.M. Fauser, Basil C. Tarlatzis, Robert W. Rebar. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility 2012; 97 (1): 28—38.
  2. PCOS Consensus Workshop Group. Rotterdam ESHRE/ ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility Sterility 2004; 81 (1): 19—25.
  3. Balen A.H., Michelmore K. What is polycystic ovary syndrome? Are national views important? Human reproduction 2002; 17: 2219—27.
  4. Ehrmann D.A., Barnes R.B., Rosenfield R.L.,et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22 (1): 141—6.
  5. Legro R.S., Kunselman A.R., Dodson W.C. et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. The Journal of Clinical Endocrinology and Metabolism 1999; 84 (1): 165—9.
  6. Azziz R., Woods K.S., Reyna R. et. al. The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology and Metabolism 2004; 89 (6): 2745—9.
  7. Dunaif A. et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165—74.
  8. Erhmann D.A. et al. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenizm due to dysregulation of androgen secretion. Endocrine Reviews 1995; 16: 322—53.
  9. Dunaif A., et al. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 1997; 18: 774—800.
  10. Jang-Yen Wu, Howard Prentice. Role of taurine in the central nervous system. From 17th International Meeting of Taurine. Fort Lauderdale, FL, USA. 14—19 December 2009. Journal of biomedical science 2010; 17 (Suppl. 1): S1—6.
  11. Stephen W. Schaffer, Chian Ju Jong, Kamila K.C. et al. Physiological roles of taurine in heart and muscle. From 17th International Meeting of Taurine. Fort Lauderdale, FL, USA. 14—19 December 2009. Journal of biomedical science 2010; 17 (Suppl. 1): S1—8.
  12. Yukio Yamori, Takashi Taguchi, Atsumi Hamada. et al. Taurine in health and deseases: consistent evidence from experimental and epidemiological studies. From 17th International Meeting of Taurine. Fort Lauderdale, FL, USA. 14-19 December 2009. Journal of biomedical science 2010; 17 (Suppl. 1): S1—24.
  13. William L’ Amoreaux , Cristina Cuttitta, Alison Santora. et al. Taurine regulates insulin release from pancreatic beta-sell lines. From 17th International Meeting of Taurine. Fort Lauderdale, FL, USA. 14—19 December 2009. Journal of biomedical science 2010; 17 (Suppl. 1) S11: 1—8.
  14. Yutaka Nakaya, Asako Minami, Nagakatsu Harada. et al. Taurine improves insulin sensitivity in the Otsuka Long-EvansTokushima Fatty rat, a model of spontaneous type 2 diabetes. The American Journal of Clinical Nutrition 2000; 71: 54—8.
  15. Seghieri G., Tesi F., Bianchi L. et al. Taurine in women with a history of gestational diabetes. Diabetes Research and Clinical Practice 2007; 76(2): 187—92.
  16. Friedewald W.T. et al. Estimation of the concentration of LDL cholesterol in plasma without the preparative ultracentrifuge. Clin Chemistry 1972; 18: 499—502
  17. Stumvoll M. et al. Use of the OGTT to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295—301.
  18. Hye Min Kim, Chang-Hee Do, Dong He Lee. Characterization of taurine as anti-obesity agent in C. elegans. From 17th International Meeting of Taurine. Fort Lauderdale, FL, USA. 14—19 December 2009. Journal of biomedical science 2010; 17 (Suppl. 1) S33: 1—6.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies